These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10910310)

  • 61. The effect of omeprazole or ranitidine treatment on 24-hour esophageal acidity in patients with reflux esophagitis.
    Ruth M; Enbom H; Lundell L; Lönroth H; Sandberg N; Sandmark S
    Scand J Gastroenterol; 1988 Nov; 23(9):1141-6. PubMed ID: 3073525
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.
    Kahrilas PJ; Fennerty MB; Joelsson B
    Am J Gastroenterol; 1999 Jan; 94(1):92-7. PubMed ID: 9934737
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.
    Revicki DA; Wood M; Wiklund I; Crawley J
    Qual Life Res; 1998 Jan; 7(1):75-83. PubMed ID: 9481153
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
    Chiu CT; Hsu CM; Wang CC; Chang JJ; Sung CM; Lin CJ; Chen LW; Su MY; Chen TH
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1054-64. PubMed ID: 24024757
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
    Venables TL; Newland RD; Patel AC; Hole J; Wilcock C; Turbitt ML
    Scand J Gastroenterol; 1997 Oct; 32(10):965-73. PubMed ID: 9361167
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease.
    Bardhan KD
    Aliment Pharmacol Ther; 1995; 9 Suppl 1():15-25. PubMed ID: 7495937
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
    Qvigstad G; Arnestad JS; Brenna E; Waldum HL
    Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine.
    Bianchi Porro G; Pace F; Peracchia A; Bonavina L; Vigneri S; Scialabba A; Franceschi M
    J Clin Gastroenterol; 1992 Oct; 15(3):192-8. PubMed ID: 1479161
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.
    Veldhuyzen van Zanten SJ; Chiba N; Armstrong D; Barkun A; Thomson A; Smyth S; Escobedo S; Lee J; Sinclair P
    Am J Gastroenterol; 2005 Jul; 100(7):1477-88. PubMed ID: 15984968
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
    Takenaka R; Okada H; Kawano S; Komazawa Y; Yoshinaga F; Nagata S; Inoue M; Komatsu H; Onogawa S; Kushiyama Y; Mukai S; Todo H; Okanobu H; Manabe N; Tanaka S; Haruma K; Kinoshita Y
    World J Gastroenterol; 2016 Jun; 22(23):5430-5. PubMed ID: 27340360
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ
    Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
    Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
    Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
    Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
    Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
    Eggleston A; Wigerinck A; Huijghebaert S; Dubois D; Haycox A
    Gut; 1998 Jan; 42(1):13-6. PubMed ID: 9505878
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
    Havelund T; Laursen LS; Lauritsen K
    Scand J Gastroenterol Suppl; 1994; 201():69-73. PubMed ID: 8047827
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era.
    Nayyar AK; Royston C; Bardhan KD
    Dig Liver Dis; 2003 Mar; 35(3):143-50. PubMed ID: 12779067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.